Search - tctmd.com

Displaying 61 - 80 of 143

Sort: Relevancy | Date

News Conference News AHA 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Yael L. Maxwell

November 19, 2019

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

News Daily News

Statins Started in Kids With FH Provide Benefits in Adulthood

Yael L. Maxwell

October 17, 2019

News Daily News

Walk and Talk: Step-Counting Devices Work Best When Paired With Doctor Consults

Yael L. Maxwell

October 10, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Published Cohort

News Conference News ESC 2019

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Yael L. Maxwell

September 03, 2019

News Conference News ESC 2019

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

Yael L. Maxwell

August 31, 2019

News Daily News

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Yael L. Maxwell

August 14, 2019

News Daily News

Statin Discontinuation in the Elderly Linked to More CV Events

Yael L. Maxwell

August 01, 2019

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

News Conference News SCCT 2019

Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology

Yael L. Maxwell

July 15, 2019

News Daily News

Age Without Atherosclerosis: Tests May Help Elderly Skip Statins

Yael L. Maxwell

July 04, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Daily News

AHA Advisory Emphasizes Need for Food-System Innovation, and Proof That It Works

Yael L. Maxwell

May 02, 2019

News Daily News

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

Yael L. Maxwell

April 24, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Daily News

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Yael L. Maxwell

April 18, 2019

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

Advertisement

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Statins Started in Kids With FH Provide Benefits in Adulthood

Walk and Talk: Step-Counting Devices Work Best When Paired With Doctor Consults

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

ORION-11: Inclisiran Shows Promise, Safety in Largest Cohort to Date

Evolocumab in Acute ACS Safely Reduces LDL Cholesterol: EVOPACS

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Statin Discontinuation in the Elderly Linked to More CV Events

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology

Age Without Atherosclerosis: Tests May Help Elderly Skip Statins

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

AHA Advisory Emphasizes Need for Food-System Innovation, and Proof That It Works

Will Less Aggressive Lp(a) Targets Do the Trick? Time and Clinical Trials Will Tell

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content